Krystal Biotech, Inc.
http://www.krystalbio.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Krystal Biotech, Inc.
US FDA’s Botanical Drugs Guidance Will See Rare Outing For Amryt’s Filsuvez NDA
Amryt’s birch bark extract oleogel-S10 for Epidermolysis Bullosa patients might become only the third botanical drug to clear the FDA.
Butterfly Skin Therapy Pipeline Primed For Transformation
No drugs are approved for epidermolysis bullosa and children with so-called butterfly skin are currently treated by cleaning open wounds and bandaging them. This could soon change.
Finance Watch: Argenx Raises $1.15bn For Efgartigimod Commercialization
Public Company Edition: Among other recent large financings, BridgeBio Pharma launched a $650m note sale, CureVac closed a $517.5m follow-on offering and Revolution Medicines raised $260.9m.
Amryt Flies As Butterfly Skin Therapy Hits Late-Stage Goal
Filsuvez has the potential to become the first treatment approved for epidermolysis bullosa, a rare genetic condition where skin can tear and blister at even the slightest touch.
Company Information
- Industry
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
- Topical Delivery
-
Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule